LENZ Therapeutics transitioned to a commercial-stage company following the FDA approval of VIZZ in July 2025, reporting its first product sales of $6.0 million for the nine months ended September 30, 2026. Despite the new revenue stream, the company saw a significant increase in net loss to $104.4 million for the same period, driven primarily by a surge in selling, general, and administrative expenses to $120.2 million.
Lenz Therapeutics 10% Owner Ra Capital Management L.P. Sells $9.13M of Stock
Ra Capital Management L.P., 10% Owner, sold 2,718,684 shares of Lenz Therapeutics, Inc. at $3.36 a share, worth $9.13M in total on Oct 29, 2026. Shares held after the trade: 57,559 (-65.1%).
LENZ Therapeutics reported Q3 2026 financial results featuring a 50% sequential increase in VIZZ product sales. Alongside results, the company announced a strategic reorganization reducing headcount by 75% to focus on consumer marketing and a leadership transition where CEO Eef Schimmelpennink will be succeeded by CFO Dan Chevallard as Interim CEO on December 1, 2026.
Term
Q3 2026
“Our strong third-quarter results demonstrate continued progress in the commercialization of VIZZ, with product sales growth of 50%, increasing patient adoption and encouraging refill rates. We view these as promising indicators of our positive trajectory in this emerging market.”
Eef Schimmelpennink, President and Chief Executive Officer
“After nearly six years leading LENZ and more than 25 years in the biotechnology industry, I have decided to transition from my role as CEO effective December 1, 2026, to devote more time to other passions.”
Eef Schimmelpennink, President and Chief Executive Officer